Treatment Adherence As a Cost Determinant in Patients with Tuberculosis

Author(s)

Kwon SH1, Nam JH2, Min S1, Kim HL3, Kwon JW4
1Sungkyunkwan University, Su-won, Korea, Republic of (South), 2Sungkyunkwan University, Suwon, South Korea, 3Sahmyook University, Seoul, Korea, Republic of (South), 4Kyungpook National University, Daegu, Korea, Republic of (South)

Presentation Documents

OBJECTIVES

Poor adherence to anti-tuberculosis treatment is an essential obstacle to tuberculosis (TB) control. It aims to observe all-cause/TB-related costs by TB treatment adherence and explore the association between medication adherence and medical cost in patients with TB in South Korea.

METHODS

Using claims data from the Korean National Health Insurance Service, we conducted a retrospective cohort study. Newly-treated TB patients were followed up from treatment initiation to death or end of the study. Based on the proportion of days covered (PDC), patients were categorized into adherent (PDC ⪰0.8) and non-adherent (PDC<0.8) groups. We estimated mean all-cause/TB-related cumulative cost per patient with adjusting censored costs. We also obtained monthly costs per patient during treatment and observed treatment outcomes: treatment completion, loss to follow-up from treatment, death during treatment, and initiation of multi-drug resistant TB treatment. Conclusively, we estimated relative ratios to find cost drivers using generalized linear models with adjusting baseline characteristics such as age and sex.

RESULTS

Of 3,799 newly-treated TB patients, Adherent group were 2,662 (70%) and non-adherent group were 1,137 (30%). During five years, all-cause costs were US$ 10,270 in the adherent group and US$ 10,474 in the non-adherent group, while TB-related costs were US$ 2,270 and US$ 2,694, respectively. Medication was the biggest proportion in all-cause/TB-related costs ranging from 30 to 33% in adherent and non-adherent groups. Monthly all-cause costs per patient during the treatment were also higher in the non-adherent group comparing with the adherent group (US$ 1,066 vs. US$ 2,804). The adherent group spent less on TB-related costs (relative ratio=0.89, 95% CI 0.92-0.98). Patients who lost to follow-up for treatment spent more TB-related costs (2.52, 2.24-2.83).

CONCLUSIONS

Non-adherent TB patients spend more cost on TB treatment. Therefore, improving patient adherence may lead to good treatment outcomes and a saving social budget.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSA416

Topic

Economic Evaluation

Disease

Drugs, Infectious Disease (non-vaccine), Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×